(cid:3)
`
`APTAR PHARMA PROVIDES UNIT-DOSE NASAL SPRAY TECHNOLOGY FOR
`TREATMENT OF OPIOID OVERDOSE
`
`Louveciennes, France – April 20, 2016 – Aptar Pharma announced that it has provided
`the delivery system and regulatory support for Adapt Pharma’s Narcan® which is the
`(cid:191)(cid:85)(cid:86)(cid:87)(cid:3)(cid:56)(cid:17)(cid:54)(cid:17)(cid:3)(cid:41)(cid:39)(cid:36)(cid:16)(cid:68)(cid:83)(cid:83)(cid:85)(cid:82)(cid:89)(cid:72)(cid:71)(cid:3)(cid:81)(cid:68)(cid:86)(cid:68)(cid:79)(cid:79)(cid:92)(cid:3)(cid:68)(cid:71)(cid:80)(cid:76)(cid:81)(cid:76)(cid:86)(cid:87)(cid:72)(cid:85)(cid:72)(cid:71)(cid:15)(cid:3)(cid:81)(cid:72)(cid:72)(cid:71)(cid:79)(cid:72)(cid:16)(cid:73)(cid:85)(cid:72)(cid:72)(cid:15)(cid:3)(cid:85)(cid:72)(cid:68)(cid:71)(cid:92)(cid:16)(cid:87)(cid:82)(cid:3)(cid:88)(cid:86)(cid:72)(cid:3)(cid:80)(cid:72)(cid:71)(cid:76)(cid:70)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:87)(cid:75)(cid:68)(cid:87)(cid:3)
`(cid:70)(cid:68)(cid:81)(cid:3)(cid:86)(cid:87)(cid:82)(cid:83)(cid:3)(cid:82)(cid:85)(cid:3)(cid:85)(cid:72)(cid:89)(cid:72)(cid:85)(cid:86)(cid:72)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:72)(cid:73)(cid:73)(cid:72)(cid:70)(cid:87)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:68)(cid:81)(cid:3)(cid:82)(cid:83)(cid:76)(cid:82)(cid:76)(cid:71)(cid:3)(cid:82)(cid:89)(cid:72)(cid:85)(cid:71)(cid:82)(cid:86)(cid:72)(cid:17)
`
`Working together to achieve combination drug–device product compliance and
`regulatory approval
`
`Narcan® contains naloxone which is an opioid antagonist. It is marketed in the U.S. for
`emergency treatment of known or suspected opioid overdose.
`“The U.S is facing an unprecedented opioid overdose epidemic.
`
`By making Narcan® Nasal Spray available, we hope to increase
`everyone’s access to emergency treatments across the U.S.,”
`said Seamus Mulligan, Chairman and CEO of Adapt Pharma.
`
`Aptar Pharma has brought to the partnership its unique
`experience in nasal drug delivery and regulatory expertise
`in relation to combination drug-device products successfully
`supporting Adapt Pharma’s new drug application.
`
`Courtesy of Adapt Pharma
`
`“Aptar Pharma leads the industry in nasal drug delivery expertise. We have collaborated
`closely with Adapt Pharma to ensure the rapid approval of this potentially life-saving product
`using our Unit-dose System (UDS). The regulations and requirements for market approvals
`are rapidly evolving and customers must seek out trusted partners like Aptar Pharma. We are
`continually investing in resources and capabilities to support our customers in reaching the
`market quickly,” said Salim Haffar, President of Aptar Pharma.
`
`(cid:38)(cid:82)(cid:81)(cid:87)(cid:76)(cid:81)(cid:88)(cid:82)(cid:88)(cid:86)(cid:3)(cid:72)(cid:91)(cid:83)(cid:68)(cid:81)(cid:86)(cid:76)(cid:82)(cid:81)(cid:3)(cid:82)(cid:73)(cid:3)(cid:81)(cid:82)(cid:81)(cid:16)(cid:76)(cid:81)(cid:89)(cid:68)(cid:86)(cid:76)(cid:89)(cid:72)(cid:3)(cid:81)(cid:68)(cid:86)(cid:68)(cid:79)(cid:3)(cid:86)(cid:83)(cid:85)(cid:68)(cid:92)(cid:86)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:54)(cid:92)(cid:86)(cid:87)(cid:72)(cid:80)(cid:76)(cid:70)(cid:3)(cid:39)(cid:85)(cid:88)(cid:74)(cid:3)(cid:39)(cid:72)(cid:79)(cid:76)(cid:89)(cid:72)(cid:85)(cid:92)(cid:3)
`
`Estimated at over $2 billion in 2015, the world market for intra-nasal spray systemic drug
`delivery has experienced strong growth in the last few years. The list of therapies successfully
`treated via the nasal route continues to grow from the traditional areas of migraine, osteoporosis
`and endometriosis, to now include: post-operative pain (ketorolac), cancer pain (fentanyl),
`osteoporosis, prostate cancer, urinary incontinence, anemia and vaccinations.
`
`Nalox1018
`Nalox-1 Pharmaceuticals, LLC
`Page 1 of 2
`
`

`

`(cid:3)
`
`(cid:56)(cid:39)(cid:54)(cid:29)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:83)(cid:85)(cid:82)(cid:89)(cid:72)(cid:81)(cid:3)(cid:87)(cid:72)(cid:70)(cid:75)(cid:81)(cid:82)(cid:79)(cid:82)(cid:74)(cid:92)(cid:3)(cid:83)(cid:79)(cid:68)(cid:87)(cid:73)(cid:82)(cid:85)(cid:80)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:88)(cid:81)(cid:76)(cid:87)(cid:16)(cid:71)(cid:82)(cid:86)(cid:72)(cid:3)(cid:79)(cid:76)(cid:84)(cid:88)(cid:76)(cid:71)(cid:3)(cid:71)(cid:85)(cid:88)(cid:74)(cid:3)(cid:71)(cid:72)(cid:79)(cid:76)(cid:89)(cid:72)(cid:85)(cid:92)
`
`Aptar Pharma’s UDS is the preferred liquid spray drug delivery technology platform when
`dose accuracy and ease of administration are critical. The single-shot UDS system’s primeless
`feature combined with 360° orientation offer the patient or the caregiver unique ready-to-use
`convenience.
`
`About Aptar Pharma
`
`Aptar Pharma is a part of the AptarGroup family of companies, along with
`Aptar Beauty + Home and Aptar Food + Beverage.
`
`AptarGroup, Inc. is a leading global supplier of a broad range of innovative dispensing
`solutions for the beauty, personal care, home care, prescription drug, consumer health care,
`injectables, food, and beverage markets.
`
`AptarGroup is headquartered in Crystal Lake, Illinois, with manufacturing facilities in
`North America, Europe, Asia and South America.
`To learn more, visit www.aptar.com/pharma.
`
`Press Contacts
`
`Elisa Eschylle, Events and Press Relations Manager
`Tel.: + 33 (0)1 39 17 20 41 – Email: elisa.eschylle@aptar.com
`
`Marion Baschet Vernet, Press Attaché
`Tel.: + 33 (0)6 22 17 08 96 – Email: mbvernet@gmail.com
`
`Nalox1018
`Nalox-1 Pharmaceuticals, LLC
`Page 2 of 2
`
`